Citadel Advisors’s Soleno Therapeutics SLNO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-73,100
| Closed | -$2.45M | – | 14755 |
|
|
2026
Q1 | $2.45M | Sell |
73,100
-124,400
| -63% | -$4.88M | ﹤0.01% | 5669 |
|
|
2025
Q4 | $9.14M | Buy |
197,500
+107,700
| +120% | +$5.91M | ﹤0.01% | 3383 |
|
|
2025
Q3 | $6.07M | Sell |
89,800
-52,000
| -37% | -$3.86M | ﹤0.01% | 4009 |
|
|
2025
Q2 | $11.9M | Buy |
141,800
+83,700
| +144% | +$6.26M | ﹤0.01% | 2791 |
|
|
2025
Q1 | $4.15M | Sell |
58,100
-132,700
| -70% | -$6.46M | ﹤0.01% | 4197 |
|
|
2024
Q4 | $8.58M | Buy |
190,800
+160,600
| +532% | +$8.32M | ﹤0.01% | 3182 |
|
|
2024
Q3 | $1.52M | Buy |
30,200
+11,700
| +63% | +$560K | ﹤0.01% | 6019 |
|
|
2024
Q2 | $755K | Buy |
18,500
+8,700
| +89% | +$369K | ﹤0.01% | 7178 |
|
|
2024
Q1 | $419K | Buy |
9,800
+9,400
| +2,350% | +$425K | ﹤0.01% | 8765 |
|
|
2023
Q4 | $16.1K | Buy |
+400
| New | +$11.4K | ﹤0.01% | 12809 |
|
|
2022
Q1 | – | Sell |
-4,420
| Closed | -$27K | – | 14488 |
|
|
2021
Q4 | $27K | Sell |
4,420
-1,600
| -27% | -$16.8K | ﹤0.01% | 13507 |
|
|
2021
Q3 | $83K | Sell |
6,020
-3,127
| -34% | -$43.6K | ﹤0.01% | 13043 |
|
|
2021
Q2 | $156K | Buy |
9,147
+1,054
| +13% | +$17.8K | ﹤0.01% | 12462 |
|
|
2021
Q1 | $153K | Buy |
+8,093
| New | +$261K | ﹤0.01% | 12005 |
|
|
2020
Q4 | – | Sell |
-1,020
| Closed | -$38K | – | 11479 |
|
|
2020
Q3 | $38K | Sell |
1,020
-1,087
| -52% | -$31.8K | ﹤0.01% | 9685 |
|
|
2020
Q2 | $70K | Buy |
+2,107
| New | +$91.3K | ﹤0.01% | 9163 |
|
Citadel Advisors's SLNO Position: Q2 2026 in Review
Citadel Advisors sold out of Soleno Therapeutics (SLNO) in Q2 2026, closing a stake of 386,545 shares — an estimated $12.9M sold.
Citadel Advisors first reported a position in SLNO in Q2 2015 and held it in 23 quarters. The position peaked at $126M in Q2 2025. 0 funds tracked by Wall St. Rank hold SLNO as of Q2 2026.
- Citadel Advisors reported no remaining Soleno Therapeutics position as of Q2 2026 after selling out during the quarter.
- Citadel Advisors sold 386,545 Soleno Therapeutics shares in Q2 2026, an estimated $12.9M.
- Citadel Advisors first reported a position in Soleno Therapeutics in Q2 2015 and held it in 23 quarters.
- Citadel Advisors's Soleno Therapeutics position peaked at $126M in Q2 2025.
- 0 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q2 2026.
Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.